Heartseed

Tokyo, Japan· Est. 2015

A Japanese biotech developing iPSC-derived cardiomyocyte transplantation therapies to remuscularize the heart and treat severe heart failure.

heartseed.jp

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

Private Company

Funding information not available

AI Company Overview

A Japanese biotech developing iPSC-derived cardiomyocyte transplantation therapies to remuscularize the heart and treat severe heart failure.

Cardiovascular

Technology Platform

A proprietary, integrated platform for generating, purifying, and transplanting ventricular-specific cardiomyocyte spheroids ('Heartseeds') from induced pluripotent stem cells (iPSCs) for cardiac remuscularization.

Opportunities

Addressing the massive, unmet global need in heart failure with a potentially curative cellular therapy that could reduce dependency on heart transplants and mechanical devices, with a platform extendable to autologous and hypoimmunogenic next-generation cell products.

Risk Factors

Clinical risks include demonstrating safety (particularly arrhythmogenic and tumorigenic potential), efficacy, and long-term engraftment of transplanted cells in a first-in-human trial, alongside complex manufacturing, scalability, and eventual reimbursement challenges for a novel regenerative therapy.

Competitive Landscape

Competes in the emerging field of iPSC-derived cardiomyocyte transplantation for heart failure; key differentiation lies in its ventricle-specific cell production, metabolic purification to remove undifferentiated cells, and spheroid-based ('Heartseed') delivery system designed for superior engraftment and functional integration.

More companies in Japan →